Clinical Research Directory
Browse clinical research sites, groups, and studies.
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Sponsor: Orca Biosystems, Inc.
Summary
This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.
Official title: An Expanded Access Program for Orca-T Products That Are Out of Specification for Commercial Release
Key Details
Gender
All
Age Range
Any - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-09-21
Healthy Volunteers
Not specified
Conditions
Interventions
Orca-T
Orca-T that does not meet commercial release specifications
Locations (8)
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
The University of Kansas Hospital
Kansas City, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio, United States
Baylor University Medical Center
Dallas, Texas, United States